紅血球生成刺激劑

Buzzwords → Dx

Workup before initiation

• Iron studies (Fe, TIBC, ferritin, TSAT).
• B12, folate.
• Renal function (CKD context).
• Hb baseline + trend.
• EPO level (esp. for MDS).
• Cardiovascular risk + BP control.

Indications

1. Chemo-induced anemia in non-curative-intent chemo with Hb <10 g/dL.
2. Lower-risk MDS with EPO <500 mU/mL.
3. CKD anemia (different specialty).
4. AZT-related anemia in HIV.
5. Perisurgical use to reduce transfusion (selected indications).

Contraindications / cautions

• Curative-intent chemotherapy (lung, breast, head & neck, lymphoma cures avoided).
• Active thrombotic disease.
• Uncontrolled hypertension.
• Pure red cell aplasia from prior anti-EPO antibodies.

Treatment Algorithm

flowchart TD
  A[Symptomatic anemia in chemo / MDS] --> B[Workup: iron, B12, folate, EPO, renal]
  B --> C{Cause}
  C -- chemo-induced anemia non-curative + Hb <10 --> D[Epoetin / darbepoetin per protocol]
  C -- lower-risk MDS + EPO <500 --> E[Epoetin / darbepoetin<br>add G-CSF if no response after 8 wk]
  C -- ringed sideroblasts / SF3B1 + transfusion-dependent --> F[Luspatercept first-line<br>COMMANDS]
  D --> G[Iron + folate + B12 supplementation as needed]
  E --> G
  F --> G
  G --> H[Monitor Hb q1-2 wk<br>target Hb 10-12 — DO NOT exceed 12<br>thrombosis risk]
  H --> I{Adequate response by 8-12 wk?}
  I -- yes --> J[Continue + adjust dose]
  I -- no --> K[Discontinue ESA<br>switch to luspatercept (MDS-RS) or transfusion]

Pearls / Pitfalls

• Curative-intent chemo + ESA = bad outcomes. Multiple meta-analyses showed worse OS — use restrictive transfusion threshold + iron + folate optimization instead.
• Hb target 10-12 g/dL — overshooting >12 increases thrombosis. Don't aim for normal Hb.
• EPO level <500 mU/mL predicts response in MDS — lower-risk MDS-EPO low responders. EPO ≥500 → poor response, consider luspatercept or transfusion.
• Iron + ESA: ESA depletes iron stores; supplement to ferritin >100 + TSAT >20 % for adequate response.
• Anti-EPO antibodies + PRCA — rare with current formulations; was problem with older preparations.
• HIF-PHIs (oral) for CKD anemia approved (e.g., roxadustat in EU, daprodustat in US for CKD); not yet established for cancer-related anemia.
• Luspatercept (Reblozyl) for transfusion-dependent lower-risk MDS-RS / β-thal — works downstream of EPO; q3 wk SC; first-line in COMMANDS trial vs ESA for transfusion-dependent SF3B1+/ringed sideroblast MDS.
• ESA in cancer requires REMS program enrollment in some countries (US ESA APPRISE).

Cross-references

• MDS — luspatercept and ESA
• Iron + ESA optimization
• Luspatercept for β-thal
• Drug Regimens — epoetin, darbepoetin, luspatercept

相關題目

• Q-199 — ESA — chemo-induced anemia indication
• Q-200 — ESA — contraindication in curative-intent chemo
• Q-201 — ESA — EPO level threshold in MDS

Sources